Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM3B | Q7LBC6 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM6B | O15054 | 1/20 | 0.37 |
| ▸ | KDM4A | O75164 | 1/20 | 0.37 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.37 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1210851 | 0.82 | KDM3B (0.69) | KDM3BKDM4EKMT2ATDP1GAA | |
| SCHEMBL21246609 | 0.79 | KDM3B (0.65) | KDM3BKDM4EKMT2ATDP1 | |
| SCHEMBL127493 | 0.78 | KDM3B (0.64) | KDM3BKDM4EGAAHPGDHSD17B10 | |
| SCHEMBL9443874 | 0.78 | KDM3B (0.60) | KDM3BKDM4EKMT2ATDP1GAA | |
| SCHEMBL10001205 | 0.77 | KDM3B (0.62) | KDM3BKDM4EKMT2ATDP1GAA | |
| SCHEMBL12872720 | 0.77 | KDM3B (0.62) | KDM3BKDM4EKMT2ATDP1GAA | |
| Hydrochloric Acid SCHEMBL11439523 | 0.77 | KDM3B (0.62) | KDM3BKDM4EGAAHPGDHSD17B10 | |
| Water SCHEMBL4487821 | 0.77 | KDM3B (0.62) | KDM3BKDM4EGAAHPGDHSD17B10 | |
| SCHEMBL1810204 | 0.73 | KMT2A (0.61) | KDM3BKDM4EKMT2ATDP1GAA | |
| Dimethylamine SCHEMBL1524840 | 0.72 | KDM3B (0.56) | KDM3BKDM4EKMT2AGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116462633-A | Modified opening agent and preparation method thereof, and easily-printed modified biodegradable material and preparation method thereof | 万华化学（宁波）有限公司 | 2023-07-21 | — | — | CN | claimed |
| EP-1206551-B2 | ENZYMATIC SYNTHESIS OF DEOXYRIBONUCLEOSIDES | PASTEUR INSTITUT (FR) | 2011-10-26 | — | — | EP | claimed |
| EP-1625234-B1 | BIOSYNTHETIC LABELING AND SEPARATION OF RNA | UNIV LELAND STANFORD JUNIOR (US) | 2009-08-19 | — | — | EP | claimed |
| EP-1206551-B1 | ENZYMATIC SYNTHESIS OF DEOXYRIBONUCLEOSIDES | PASTEUR INSTITUT (FR) | 2009-05-13 | — | — | EP | claimed |
| US-20080280329-A1 | Enzymatic synthesis of deoxyribonucleosides | TISCHER WILHELM | 2008-11-13 | — | — | US | claimed |
| US-7229797-B1 | Enzymatic synthesis of deoxyribonucleosides | INSTITUT PASTEUR (FR) | 2007-06-12 | — | — | US | claimed |
| EP-1206551-A2 | ENZYMATIC SYNTHESIS OF DEOXYRIBONUCLEOSIDES | Roche Diagnostics GmbH (DE) | 2002-05-22 | — | — | EP | claimed |
| WO-2001014566-A2 | ENZYMATIC SYNTHESIS OF DEOXYRIBONUCLEOSIDES | ROCHE DIAGNOSTICS GMBH (DE) | 2001-03-01 | — | — | WO | claimed |
| JP-10001473-A | — | — | None | — | — | JP | disclosed |
| US-12054768-B2 | Methods for detecting agglutination and compositions for use in practicing the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-08-06 | — | — | US | disclosed |
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | SPIRAL THERAPEUTICS INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | SPIRAL THERAPEUTICS INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | SPIRAL THERAPEUTICS INC. | 2023-09-21 | — | — | US | disclosed |
| CN-116462633-A | Modified opening agent and preparation method thereof, and easily-printed modified biodegradable material and preparation method thereof | 万华化学（宁波）有限公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-1992020816-A1 | DETERMINATION OF PRODRUGS METABOLIZABLE BY THE LIVER AND THERAPEUTIC USE THEREOF | YALE UNIVERSITY (US) | 1992-11-26 | — | — | WO | disclosed |
| EP-0504279-A1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES. | CHEMGEN CORP (US) | 1992-09-23 | — | — | EP | disclosed |
| WO-1991009130-A1 | FERMENTATION PROCESS FOR THE PRODUCTION OF PYRIMIDINE DEOXYRIBONUCLEOSIDES | CHEMGEN CORPORATION (US) | 1991-06-27 | — | — | WO | disclosed |
| EP-0280128-A2 | Process for the preparation of 1-(3-azido-2,3-dideoxy-beta-D-erythro-pentofuranoxyl) pyrimidines, and intermediates | BAYER AG (DE) | 1988-08-31 | — | — | EP | disclosed |
| EP-0263740-A1 | Coupling conjugates between RNA or DNA sequences and a protein, method for their preparation and their biological use | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1988-04-13 | — | — | EP | disclosed |
| US-3993661-A | Quinone methide photograhpic reagent precursors | POLAROID CORPORATION (US) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | OTC, SLC26A4, OAT | KDM3B 3596/4885KDM4E 4100/4885KMT2A 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.